Review
Open access
Oct 2026
Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC–ICI combinations, and global real-world integration
This focused narrative review examines how biomarkers can distinguish established treatment eligibility from investigational strategies intended to address immune exclusion and resistance in triple-negative breast cancer.
Jing-Na Wu
· Frontiers in Immunology · 0 citations